Yifan Pharmaceutical Co. Ltd. (002019)
XSHE XSHE Primary Summary
002019 Chart
People also search for
Yifan Pharmaceutical Co. Ltd. (002019) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Yifan Pharmaceutical Co. Ltd. ever had a stock split?
Yifan Pharmaceutical Co. Ltd. Profile
| Pharmaceuticals Industry | Healthcare Sector | Mr. Xian Feng Cheng CEO | XSHE Exchange | CNE000001K65 ISIN |
| CN Country | 4,098 Employees | 29 May 2026 Last Dividend | 16 May 2016 Last Split | 28 Jun 2004 IPO Date |
Overview
Yifan Pharmaceutical Co., Ltd. is a prominent enterprise specializing in the research, development, production, and global marketing of a wide range of pharmaceutical products. Operating in key regions such as Southeast Asia, Europe, North America, along with countries like Singapore, South Korea, Italy, Germany, and the United States, Yifan Pharmaceutical has established a significant international presence. Initially known as Yifan Xinfu Pharmaceutical Co., Ltd., the company underwent a rebranding in October 2016 to align with its evolving business scope and vision. Since its inception in 2000, headquartered in Hangzhou, China, Yifan Pharmaceutical has grown into a leader in the pharmaceutical industry, focusing on therapeutic areas such as hematologic malignancies, inflammation, endocrinology/metabolism, dermatology, gynecology, and pediatrics among others.
Products and Services
Oral Slow Controlled Release Preparations: These are advanced pharmaceutical formulations designed to release a medication at a predetermined rate in order to achieve a constant drug concentration for a specific period of time, enhancing therapeutic effectiveness and patient compliance.
Micron Suspensions: This technology offers a means to improve the solubility and bioavailability of poorly water-soluble drugs, facilitating more effective treatments.
Micelles for Injection: Utilizing nanotechnology, these are designed to improve the delivery and effectiveness of drugs, particularly in the treatment of various cancers and other serious conditions.
Liquid Preparations: Yifan Pharmaceutical provides a range of liquid formulations designed for ease of use and improved patient compliance, catering to both pediatric and adult populations.
Focus Areas: The company’s research and development efforts are geared towards addressing unmet medical needs in several key therapeutic areas, including hematologic malignances, inflammatory and endocrinology/metabolic diseases, dermatological and gynecological conditions, and pediatric ailments. This diverse portfolio underscores Yifan Pharmaceutical’s commitment to enhancing healthcare outcomes across a broad spectrum of patient populations.
